PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30954631-17 2019 CONCLUSION AND IMPLICATIONS: Serelaxin (human recombinant relaxin-2) treatment induces significant changes in cardiac major components of the membrane lipid bilayer such as glycerophospholipids and sphingolipids, known to have structural roles but also very relevant regulatory effects in cardiac function. Sphingolipids 198-211 relaxin 2 Homo sapiens 58-67